ArticleJournal of the American Society of Nephrology : JASN2008
Medical costs of abnormal serum sodium levels.
Article in Journal of the American Society of Nephrology : JASN, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Trial
- Social Impact and Economic Burden of Uncoded Hyponatremia in Elderly - A Cost-of-Illness Study.ClinicoEconomics and outcomes research : CEOR · 2026Article
- A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases.Journal of the American Society of Nephrology : JASN · 2025Article
- Molecular and physical technologies for monitoring fluid and electrolyte imbalance: A focus on cancer population.Clinical and translational medicine · 2021Review
- Development of Flexible Ion-Selective Electrodes for Saliva Sodium Detection.Sensors (Basel, Switzerland) · 2021Article
- Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer.International urology and nephrology · 2021Article
- Efficacy of oral tolvaptan versus 3% hypertonic saline for correction of hyponatraemia in post-operative patients.Indian journal of anaesthesia · 2017Article
- Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives.Cancer management and research · 2016Review
- SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Observational
- Current treatment practice and outcomes. Report of the hyponatremia registry.Kidney international · 2015Article
- Dehydration in the Elderly: A Review Focused on Economic Burden.The journal of nutrition, health & aging · 2015Review
- Risk of thiazide-induced metabolic adverse events in older adults.Journal of the American Geriatrics Society · 2014Observational
- Hyponatremia in patients with heart failure.World journal of cardiology · 2013Review
- Lixivaptan - an evidence-based review of its clinical potential in the treatment of hyponatremia.Core evidence · 2013Article
- Clinical management of SIADH.Therapeutic advances in endocrinology and metabolism · 2012Article
- Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure.Circulation · 2012Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An abnormal serum sodium level is the most common electrolyte disorder in the United States and can have a significant impact on morbidity and mortality. The direct medical costs of abnormal serum sodium levels are not well understood. The impact of hyponatremia and hypernatremia on 6-mo and 1-yr direct medical costs was examined by analyzing data from the Integrated HealthCare Information Services National Managed Care Benchmark Database. During the period analyzed, there were 1274 patients (0.8%) with hyponatremia (serum sodium <135 mmol/L), 162,829 (97.3%) with normal serum sodium levels, and 3196 (1.9%) with hypernatremia (>145 mmol/L). Controlling for age, sex, region, and comorbidities, hyponatremia was a significant independent predictor of costs at 6 mo (41.2% increase in costs; 95% confidence interval, 30.3% to 53.0%) and at 1 yr (45.7% increase; 95% confidence interval, 34.2% to 58.2%). Costs associated with hypernatremia were not significantly different from those incurred by patients with normal serum sodium. In conclusion, hyponatremia is a significant independent predictor of 6-mo and 1-yr direct medical costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.